|Day's Range||0.04 - 0.04|
|52 Week Range||0.01 - 0.09|
|PE Ratio (TTM)||-0.01|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On Jan 19, Amarantus (AMBS) and Avant Diagnostics (AVDX) announced they have entered into a Letter of Intent to merge an Amarantus wholly-owned subsidiary, Amarantus Diagnostics, into Avant Diagnostics. Under the terms of the LOI, upon execution of definitive merger agreements, Avant shall issue to Amarantus 80 million shares of common stock of Avant Diagnostics, representing approximately 45% of Avant's post-merger common stock, and 10 million additional shares of common stock upon achievement of certain sales milestones.
By Grant Zeng, CFA Earlier this morning (Feb 22), Amarantus (OTCQB: AMBS), provided an update on the status of its cGMP manufacturing technical transfer for producing ESS at Lonza Walkersville, Inc., a ...
Eltoprazine is a small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression. Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established safety profile.